EP2432328A1 - Fat blends and uses thereof - Google Patents

Fat blends and uses thereof

Info

Publication number
EP2432328A1
EP2432328A1 EP10725974A EP10725974A EP2432328A1 EP 2432328 A1 EP2432328 A1 EP 2432328A1 EP 10725974 A EP10725974 A EP 10725974A EP 10725974 A EP10725974 A EP 10725974A EP 2432328 A1 EP2432328 A1 EP 2432328A1
Authority
EP
European Patent Office
Prior art keywords
blend
acid
weight
fat blend
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10725974A
Other languages
German (de)
French (fr)
Inventor
Luisa Gambelli
Hiskias Keiser
Sebastiano Banni
Ulrike Schmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stepan Specialty Products LLC
Original Assignee
Stepan Specialty Products LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stepan Specialty Products LLC filed Critical Stepan Specialty Products LLC
Priority to EP10725974A priority Critical patent/EP2432328A1/en
Publication of EP2432328A1 publication Critical patent/EP2432328A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1315—Non-milk proteins or fats; Seeds, pulses, cereals or soja; Fatty acids, phospholipids, mono- or diglycerides or derivatives therefrom; Egg products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/003—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates to fat blends and to their uses.
  • the invention relates to fat blends which can increase the levels of essential fatty acids in the body.
  • Docosahexaenoic acid (commonly known as DHA; 22:6( ⁇ -3), a//-c/s-docosa- 4,7,10,13,16,19-hexa-enoic acid) is an omega-3 essential fatty acid.
  • DHA is present in fish oils and is frequently taken as a nutritional supplement for its health benefits.
  • DHA is the most abundant essential fatty acid in the brain and the retina and is believed to be beneficial in the treatment or prevention of many conditions and disorders including heart disease and disorders of the brain.
  • DHA is provided by the diet or is synthesised from eicosapentaenoic acid (EPA).
  • EPA is either derived directly from the diet or is synthesised from alpha-linolenic acid (ALA).
  • ALA is another essential fatty acid and is present in relatively large amounts in oils such as linseed oil.
  • compositions containing ALA and CLA can increase DHA levels.
  • the presence of oleic acid in the fat blend, in combination with the ALA and CLA, has been found to be important.
  • WO 2007/096148 discloses the unrelated use of a conjugated fatty acid for enhancing immune system development.
  • a diet used in the examples contains 8.6 % ALA, 11.2 % CLA and 19 % oleic acid, based on the weight of the fatty acids present.
  • WO 2005/063230 relates to the use of conjugated linolenic acids for another unrelated use, which is reducing body fat mass. All of the diets were relatively low in CLA content.
  • compositions that can increase the level of DHA in a subject when they are consumed.
  • DHA which is usually derived from fish or algae. Both algal DHA and DHA from fish tend to have problems of poor taste and DHA from fish is unacceptable to vegetarians.
  • the present invention provides fat blends comprising alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and oleic acid, wherein the fat blend comprises:
  • alpha-linolenic acid ALA
  • CLA conjugated linoleic acid
  • the percentages being based on the total weight of C16 to C20 fatty acids in the blend.
  • the invention provides the use of a fat blend comprising alpha- linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, for increasing the levels of docosahexaenoic acid (DHA) in the blood of a subject by oral consumption.
  • ALA alpha- linolenic acid
  • CLA conjugated linoleic acid
  • DHA docosahexaenoic acid
  • the invention provides a fat blend comprising alpha- linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, for increasing the levels of docosahexaenoic acid (DHA) in the blood of a subject by oral consumption.
  • ALA alpha- linolenic acid
  • CLA conjugated linoleic acid
  • DHA docosahexaenoic acid
  • Also provided by the invention is a method for increasing the levels of docosahexaenoic acid (DHA) in the blood of a subject which comprises providing the subject with a fat blend comprising alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, for oral consumption.
  • DHA docosahexaenoic acid
  • ALA alpha-linolenic acid
  • CLA conjugated linoleic acid
  • the invention also provides the use of a fat blend comprising alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, in the manufacture of a composition for treating or preventing one or more conditions selected from neurodegenerative diseases, depression, Alzheimer's disease, obesity and cardiovascular disease.
  • ALA alpha-linolenic acid
  • CLA conjugated linoleic acid
  • the invention also provides the use of a fat blend comprising alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, in the manufacture of a composition for improving one or more of brain function, brain development, retinal function and retinal development.
  • ALA alpha-linolenic acid
  • CLA conjugated linoleic acid
  • a foodstuff or nutritional supplement comprising a fat blend of the invention.
  • the invention is based on the finding that certain compositions can increase the level of DHA when orally consumed.
  • compositions used in the invention are fat blends.
  • the fat blends comprise alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and oleic acid.
  • ALA alpha-linolenic acid
  • CLA conjugated linoleic acid
  • oleic acid oleic acid
  • the fat blends of the invention comprise:
  • the CLA, ALA and oleic acid may take different chemical forms in the fat blends of the invention.
  • the CLA, ALA and oleic acid may independently be in the form of free acids, salts or esters, or combinations thereof.
  • at least the ALA and the oleic acid are in the form of triglycerides, most preferably, all of the ALA, CLA and oleic acid are in the form of triglycerides.
  • Suitable salts are non-toxic, pharmaceutically acceptable and/or acceptable for use in food products and/or pharmaceuticals and include, for example, salts with alkali metals and alkaline earth metals such as sodium, calcium and magnesium, preferably sodium.
  • Suitable esters include, for example, mono-, di- and triglycerides and mixtures thereof, and C 1 to C 6 alkyl esters (where the alkyl group can be straight chain or branched), as well as esters formed with alcohols that are acceptable in food products or pharmaceutical products, such as are disclosed in EP-A-1167340, the contents of which are incorporated by reference herein.
  • the fat blends of the invention will typically contain C12 to C24 fatty acids other than ALA, CLA and oleic acid.
  • fatty acid refers to straight chain, saturated or unsaturated carboxylic acids having from 12 to 24 carbon atoms.
  • the fatty acids may be present as free fatty acids, esters or salts, or combinations thereof, and will usually be in the form of glycerides, most preferably triglycerides.
  • Alpha-linolenic acid is typically present in the fat blend in an amount of from 5 to 30% by weight, more preferably from 6 to 25 % by weight based on the total weight of C16 to C20 fatty acids in the blend.
  • the ALA may be present as a free fatty acid, an ester or a salt, or a combination thereof, and will usually be in the form of a glyceride, most preferably the triglyceride.
  • At least a part of the alpha-linolenic acid (ALA) in the blend is preferably provided by the presence in the fat blend of linseed (flaxseed) oil.
  • Other sources of ALA include, for example, rapeseed (canola), soybeans and walnuts.
  • Oleic acid is preferably present in the fat blend in an amount of from 20 to 50 % by weight, more preferably from 25 to 40 % by weight based on the total weight of C16 to C20 fatty acids in the blend.
  • the oleic acid may be present as a free fatty acid, an ester or a salt, or a combination thereof, and will usually be in the form of a glyceride, most preferably the triglyceride.
  • At least a part of the oleic acid in the blend is preferably provided by the presence in the fat blend of olive oil.
  • Olive oil typically contains relatively high levels of oleic acid.
  • CLA is typically present in the fat blend in an amount of from 12 to 50 % by weight, more preferably from 16 to 45 % by weight based on the total weight of C16 to C20 fatty acids in the blend.
  • the CLA may be present as a free fatty acid, an ester or a salt, or a combination thereof, and will usually be in the form of a glyceride, most preferably the triglyceride.
  • the CLA may comprise one isomer or a mixture of two or more different isomers including: cis, cis; cis, trans; trans, cis; and trans, trans isomers.
  • Preferred isomers are the transiO, cis12 and cis9, trans 11 isomers, including these isomers in relatively pure form, as well as mixtures with each other and/or mixtures with other isomers.
  • the CLA comprises transiO, cis12 and cis9, trans11 isomers and the weight ratio of transiO, cis12 isomer to cis9, trans11 isomer, or vice versa, is at least 1.2:1, such as 1.3:1 , even more preferably at least 1.5:1 , e.g., in the range 1.5:1 to 100:1 or 1.5:1 to 10:1 , such as a 60:40 or 80:20 mixture of the transiO, cis12: cis9, trans11 isomers.
  • compositions comprising the cis9, trans11 isomer as the major isomer component i.e., present in an amount of at least 55 %, preferably at least 60 %, more preferably at least 70 %, even more preferably at least 75 %, most preferably at least 80 %, such as at least 90 % or even 100 % by weight based on the total amount of CLA.
  • CLA can be produced in conventional ways.
  • CLA can be produced by known methods, such as that described in EP-A-902082, the contents of which are incorporated herein by reference.
  • CLA enriched in one or more isomers is disclosed in WO 97/18320, the contents of which are also incorporated herein by reference.
  • the preferred fat blends of the invention comprise linseed oil, olive oil and a source of conjugated linoleic acid (CLA).
  • the invention contemplates a fat blend comprising linseed oil, olive oil and CLA.
  • One particularly preferred fat blend of the invention comprises:
  • Another preferred fat blend of the invention comprises:
  • the fat blends of the invention are suitable for human consumption and are preferably adapted for human consumption.
  • the fat blends can be consumed as such but are preferably formulated into food products or nutritional supplements.
  • the fat blends of the invention are preferably consumed at a different time from a meal, for example, at least 30 minutes, more preferably at least one hour, before or after a meal.
  • Suitable food products that may comprise the fat blends of the invention include, for example: margarines; low fat spreads; very low fat spreads; bicontinuous spreads; water continuous spreads; confectionery products, such as chocolates, coatings or fillings; ice creams; ice cream coatings; ice cream inclusions; dressings; mayonnaises; sauces; bakery fats; shortenings; cheese; meal replacement products; health bars; muesli bars; drinks; dairy products; low carbohydrate products; low calorie products; soups; cereals; and milk shakes.
  • product forms for the fat blends of the invention are nutritional supplements (which term includes food supplements), such as in the form of a soft gel or a hard capsule preferably comprising an encapsulating material selected from the group consisting of gelatin, glycerol, starch, modified starch, starch derivatives such as glucose, sucrose, lactose and fructose.
  • the encapsulating material may optionally contain cross-linking or polymerizing agents, stabilizers, antioxidants, light absorbing agents for protecting light- sensitive fills, preservatives and the like.
  • the unit dosage of the fat blend in the food supplements is from 1 mg to 1000 mg (more preferably from 100 mg to 750 mg).
  • the amount of the fat blend that is used in a unit dosage form is preferably from 100 mg to 2000 mg, for example 250 mg to 1500 mg (e.g., 750 mg), for example for taking four times a day.
  • compositions of the invention may contain other additives that are well known in the art of food and pharmaceutical products including, but not limited to, flavouring ingredients, colouring agents, sweeteners and emulsifiers.
  • certain fat blends are useful for increasing the levels of docosahexaenoic acid (DHA) in the blood of a subject by oral consumption.
  • the fat blends comprise ALA, CLA and greater than 15 %, more preferably greater than 20 %, such as greater than 30% or greater than 40 %, by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend.
  • the ratio of ALA/CLA is from 0.3 to 0.6.
  • the fat blends will be fat blends of the invention as defined above.
  • the invention provides a method for increasing the levels of DHA in the blood of a subject which comprises providing the subject with a fat blend of the invention for oral consumption.
  • the fat blend is typically simply provided to the subject for oral consumption, either in the form of the fat blend itself, a food product or a nutritional supplement.
  • the subject is in need of increasing the level of DHA in the blood.
  • the subject is preferably a mammal, most preferably a human.
  • the fat blends of the invention may be used to increase the level of DHA in vitro. This may have a number of benefits.
  • the fat blends may be useful in treating or preventing one or more conditions selected from neurodegenerative diseases, depression, Alzheimer's disease, obesity and cardiovascular disease.
  • the fat blends may be useful for improving one or more of brain function, brain development, retinal function and retinal development.
  • the invention may involve the use of oleic acid to increase the effect of ALA and CLA in increasing the level of DHA in vitro, for example in fat blends according to the invention.
  • Rats were fed different levels of ALA 1 CLA and oleic acid.
  • the dietary groups are presented in Table 1.
  • ClarinolTM G80 is CLA in the form of a triglyceride available from Lipid Nutrition BV, Wormerveer, The Netherlands.
  • Plasma levels (nmoles/ml of plasma) of DHA, ALA and CLA.
  • Figure 1 shows the linear regression of DHA plasma concentration in function to linseed oil (LO)/CLA ratio in the diet.
  • Figure 2 shows the logarithmic regression of alpha linolenic acid (ALA) and CLA plasma concentrations in function to linseed oil/CLA ratio in the diet.
  • ALA alpha linolenic acid
  • Whey protein powder (30% protein) 1.300 1.04
  • the fat blend contains 42 % ClarinolTM G80, 25 % linseed oil and 33 % olive oil and comprises:
  • a 10% pre-emulsion of the fat blend in milk is made by slowly mixing in the fat blend to milk of 60 0 C under high-shear mixing.
  • the mixture is homogenised dual-stage at 200/50 bar and the resulting emulsion is cooled to 4 0 C.
  • Dry blend sugar, milk powder and whey protein is mixed with the rest of the milk.
  • the pre-emulsion is added.
  • the milk is heated to 60 0 C, homogenized dual-stage at 160/40 bar and heated 2 minutes at 95 0 C.
  • the milk is cooled to a fermentation temperature of 32 0 C. Starter culture is added to the milk at 32 0 C and milk is fermented till pH 4.3-4.5.
  • the resulting yoghurt is cooled to about 20 "C 1 stirred and sugar syrup and fruit are added to the yoghurt.
  • Soft gel capsules are produced by rotary die processing.
  • the material for the outside shell of the capsules, the gel, and the fill are formulated separately.
  • the gel is spread into thin film to form two gelatin ribbons which are then rolled over two separate dies which determine the size and the shape of the capsules.
  • a fat blend of the invention comprising alpha-linolenic acid, conjugated linoleic acid and oleic acid is carefully dosed to a level of 500mg, 750mg or "lOOOmg oil per capsule and injected between the two gelatin ribbons which are sealed immediately afterwards by applying heat and pressure. Capsules fall from the machine and are then dried under a stream of hot air.
  • This example shows the effect of oleic acid on CLAJLO mixture in DHA formation.
  • Total fat was balanced by adding coconut oil (CO) (diets 1 and 2) or increasing CLA and linseed oil (LO) keeping the same CLA/LO ratio.
  • CO coconut oil
  • LO linseed oil
  • Total lipids were extracted from plasma using the Folch method. Aliquots were mildly saponified in order to obtain free fatty acids for HPLC analysis. Separation of fatty acids was carried out with a Hewlett-Packard 1100 HPLC system (Hewlett-Packard, Palo Alto, California, USA) equipped with a diode array detector. A C-18 lnertsil 5 ODS-2 Chrompack column (Chrompack International BV, Middleburg, The Netherlands), 5 ⁇ m particle size, 15O x 4.6 mm, was used with a mobile phase of CH 3 CN/H 2 O/CH 3 COOH (70/30/0.12, v/v/v) at a flow rate of 1.5 ml/min. Unsaturated fatty acids were detected at 200 nm. Spectra (195-315 nm) of the eluate were obtained every 1.28 s and were electronically stored. These spectra were taken to confirm the identification of the HPLC peaks.
  • Figure 3 shows linear regression of DHA plasma concentration in function to olive oil in the diet when olive oil was replaced with coconut oil.
  • Figure 4 shows linear regression of DHA plasma concentration in function to olive oil in the diet when olive oil was replaced by increasing CLA and linseed oil (LO) keeping the same CLA/LO ratio.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A fat blend comprises alpha-linolenic acid, conjugated linoleic acid and oleic acid. The fat blend comprises: (i) greater than 3 % by weight alpha-linolenic acid; (ii) greater than 12 % by weight conjugated linoleic acid; and (iii) greater than 20 % by weight oleic acid, the percentages being based on the total weight of C16 to C20 fatty acids in the blend. The fat blend may be used for increasing the levels of docosahexaenoic acid in the blood of a subject after oral consumption.

Description

Fat Blends and Uses Thereof
This invention relates to fat blends and to their uses. In particular, the invention relates to fat blends which can increase the levels of essential fatty acids in the body.
Docosahexaenoic acid (commonly known as DHA; 22:6(ω-3), a//-c/s-docosa- 4,7,10,13,16,19-hexa-enoic acid) is an omega-3 essential fatty acid. DHA is present in fish oils and is frequently taken as a nutritional supplement for its health benefits. DHA is the most abundant essential fatty acid in the brain and the retina and is believed to be beneficial in the treatment or prevention of many conditions and disorders including heart disease and disorders of the brain.
In the human body, DHA is provided by the diet or is synthesised from eicosapentaenoic acid (EPA). In turn, EPA is either derived directly from the diet or is synthesised from alpha-linolenic acid (ALA). ALA is another essential fatty acid and is present in relatively large amounts in oils such as linseed oil.
Attempts have been made to alter the levels of fatty acids, such as DHA, by supplementation of the diet with other fatty acids.
Eder et al, Journal of Animal Physiology and Animal Nutrition, 89, 2005, 45-54 describes the effect of linseed oil supplementation on the concentration of polyunsaturated fatty acids in liver phospholipids of rats fed diets containing oils rich in conjugated linoleic acid (CLA), sunflower oil or high-oleic sunflower oil. One of the diets tested contained ALA and CLA and oleic acid in respective amounts of 31 , 30 and 10 % by weight of the fatty acids present.
Attar-Bashi et al, Asia Pac J Clin Nutr, 2003, 12, suppl:S44 tested whether dietary CLA in combination with ALA could increase DHA levels compared to ALA alone and concludes that CLA does not increase DHA levels.
It has surprisingly been found, according to the invention, that certain compositions containing ALA and CLA can increase DHA levels. Moreover, the presence of oleic acid in the fat blend, in combination with the ALA and CLA, has been found to be important. WO 2007/096148 discloses the unrelated use of a conjugated fatty acid for enhancing immune system development. A diet used in the examples contains 8.6 % ALA, 11.2 % CLA and 19 % oleic acid, based on the weight of the fatty acids present.
WO 2005/063230 relates to the use of conjugated linolenic acids for another unrelated use, which is reducing body fat mass. All of the diets were relatively low in CLA content.
Bolukbasi et at, Journal of Animal and Veterinary Advances, (2007), 6(2), 262- 266, relates to the effects of CLA on broiler performance and describes a diet comprising 1.5 % olive oil and 1.2 % CLA.
There remains a need for compositions that can increase the level of DHA in a subject when they are consumed. There is also a need to provide an alternative to conventional sources of DHA, which is usually derived from fish or algae. Both algal DHA and DHA from fish tend to have problems of poor taste and DHA from fish is unacceptable to vegetarians.
Accordingly, the present invention provides fat blends comprising alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and oleic acid, wherein the fat blend comprises:
(i) greater than 3 % by weight alpha-linolenic acid (ALA); (ii) greater than 12 % by weight conjugated linoleic acid (CLA); and
(iii) greater than 20 % by weight oleic acid,
the percentages being based on the total weight of C16 to C20 fatty acids in the blend.
In another aspect, the invention provides the use of a fat blend comprising alpha- linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, for increasing the levels of docosahexaenoic acid (DHA) in the blood of a subject by oral consumption. In yet another aspect, the invention provides a fat blend comprising alpha- linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, for increasing the levels of docosahexaenoic acid (DHA) in the blood of a subject by oral consumption.
Also provided by the invention is a method for increasing the levels of docosahexaenoic acid (DHA) in the blood of a subject which comprises providing the subject with a fat blend comprising alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, for oral consumption.
The invention also provides the use of a fat blend comprising alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, in the manufacture of a composition for treating or preventing one or more conditions selected from neurodegenerative diseases, depression, Alzheimer's disease, obesity and cardiovascular disease.
The invention also provides the use of a fat blend comprising alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, in the manufacture of a composition for improving one or more of brain function, brain development, retinal function and retinal development.
Further provided by the invention is a foodstuff or nutritional supplement comprising a fat blend of the invention.
The invention is based on the finding that certain compositions can increase the level of DHA when orally consumed.
The compositions used in the invention are fat blends. The fat blends comprise alpha-linolenic acid (ALA), conjugated linoleic acid (CLA) and oleic acid.
The fat blends of the invention comprise:
(i) greater than 3 % , preferably greater than 5 %, more preferably from 7 to 65 %, such as 7 to 30 %, by weight alpha-linolenic acid (ALA); (ii) greater than 12 %, preferably greater than 15 %, more preferably from 16 to 77 %, even more preferably from 17 to 55 %, by weight conjugated linoleic acid (CLA); and
(iii) greater than 20 %, preferably from 25 to 82 %, more preferably from 25 to 45 %, by weight oleic acid.
All of the percentages are based on the total weight of C16 to C20 fatty acids in the blend.
The CLA, ALA and oleic acid may take different chemical forms in the fat blends of the invention. For example, the CLA, ALA and oleic acid may independently be in the form of free acids, salts or esters, or combinations thereof. Preferably, at least the ALA and the oleic acid are in the form of triglycerides, most preferably, all of the ALA, CLA and oleic acid are in the form of triglycerides. Suitable salts are non-toxic, pharmaceutically acceptable and/or acceptable for use in food products and/or pharmaceuticals and include, for example, salts with alkali metals and alkaline earth metals such as sodium, calcium and magnesium, preferably sodium. Suitable esters include, for example, mono-, di- and triglycerides and mixtures thereof, and C1 to C6 alkyl esters (where the alkyl group can be straight chain or branched), as well as esters formed with alcohols that are acceptable in food products or pharmaceutical products, such as are disclosed in EP-A-1167340, the contents of which are incorporated by reference herein.
The fat blends of the invention will typically contain C12 to C24 fatty acids other than ALA, CLA and oleic acid. The term "fatty acid", as used herein, refers to straight chain, saturated or unsaturated carboxylic acids having from 12 to 24 carbon atoms. The fatty acids may be present as free fatty acids, esters or salts, or combinations thereof, and will usually be in the form of glycerides, most preferably triglycerides.
Alpha-linolenic acid (ALA) is typically present in the fat blend in an amount of from 5 to 30% by weight, more preferably from 6 to 25 % by weight based on the total weight of C16 to C20 fatty acids in the blend. The ALA may be present as a free fatty acid, an ester or a salt, or a combination thereof, and will usually be in the form of a glyceride, most preferably the triglyceride. At least a part of the alpha-linolenic acid (ALA) in the blend is preferably provided by the presence in the fat blend of linseed (flaxseed) oil. Other sources of ALA include, for example, rapeseed (canola), soybeans and walnuts.
Oleic acid is preferably present in the fat blend in an amount of from 20 to 50 % by weight, more preferably from 25 to 40 % by weight based on the total weight of C16 to C20 fatty acids in the blend. The oleic acid may be present as a free fatty acid, an ester or a salt, or a combination thereof, and will usually be in the form of a glyceride, most preferably the triglyceride.
At least a part of the oleic acid in the blend is preferably provided by the presence in the fat blend of olive oil. Olive oil typically contains relatively high levels of oleic acid.
CLA is typically present in the fat blend in an amount of from 12 to 50 % by weight, more preferably from 16 to 45 % by weight based on the total weight of C16 to C20 fatty acids in the blend. The CLA may be present as a free fatty acid, an ester or a salt, or a combination thereof, and will usually be in the form of a glyceride, most preferably the triglyceride.
The CLA may comprise one isomer or a mixture of two or more different isomers including: cis, cis; cis, trans; trans, cis; and trans, trans isomers. Preferred isomers are the transiO, cis12 and cis9, trans 11 isomers, including these isomers in relatively pure form, as well as mixtures with each other and/or mixtures with other isomers. More preferably, the CLA comprises transiO, cis12 and cis9, trans11 isomers and the weight ratio of transiO, cis12 isomer to cis9, trans11 isomer, or vice versa, is at least 1.2:1, such as 1.3:1 , even more preferably at least 1.5:1 , e.g., in the range 1.5:1 to 100:1 or 1.5:1 to 10:1 , such as a 60:40 or 80:20 mixture of the transiO, cis12: cis9, trans11 isomers. Particularly preferred are compositions comprising the cis9, trans11 isomer as the major isomer component i.e., present in an amount of at least 55 %, preferably at least 60 %, more preferably at least 70 %, even more preferably at least 75 %, most preferably at least 80 %, such as at least 90 % or even 100 % by weight based on the total amount of CLA.
CLA can be produced in conventional ways. For example, CLA can be produced by known methods, such as that described in EP-A-902082, the contents of which are incorporated herein by reference. CLA enriched in one or more isomers is disclosed in WO 97/18320, the contents of which are also incorporated herein by reference.
The preferred fat blends of the invention comprise linseed oil, olive oil and a source of conjugated linoleic acid (CLA). In one aspect, the invention contemplates a fat blend comprising linseed oil, olive oil and CLA.
One particularly preferred fat blend of the invention comprises:
(i) from 15 to 25 % CLA; (ii) from 10 to 20 % ALA; and (iii) from 20 to 50 % oleic acid; all percentages being based on the total weight of C16 to C20 fatty acids in the blend.
Another preferred fat blend of the invention comprises:
(i) from 30 to 50 % CLA; (ii) from 4 to 15 % ALA; and
(iii) from 20 to 40 % oleic acid; all percentages being based on the total weight of C16 to C20 fatty acids in the blend.
It will be appreciated that the sum of the percentages for any given composition cannot exceed 100 % but that it may be less than 100 % where, for example, the composition contains other C16 to C20 fatty acids.
The fat blends of the invention are suitable for human consumption and are preferably adapted for human consumption. The fat blends can be consumed as such but are preferably formulated into food products or nutritional supplements.
The fat blends of the invention (and food products or nutritional supplements comprising them) are preferably consumed at a different time from a meal, for example, at least 30 minutes, more preferably at least one hour, before or after a meal. Suitable food products that may comprise the fat blends of the invention include, for example: margarines; low fat spreads; very low fat spreads; bicontinuous spreads; water continuous spreads; confectionery products, such as chocolates, coatings or fillings; ice creams; ice cream coatings; ice cream inclusions; dressings; mayonnaises; sauces; bakery fats; shortenings; cheese; meal replacement products; health bars; muesli bars; drinks; dairy products; low carbohydrate products; low calorie products; soups; cereals; and milk shakes.
Other examples of product forms for the fat blends of the invention are nutritional supplements (which term includes food supplements), such as in the form of a soft gel or a hard capsule preferably comprising an encapsulating material selected from the group consisting of gelatin, glycerol, starch, modified starch, starch derivatives such as glucose, sucrose, lactose and fructose. The encapsulating material may optionally contain cross-linking or polymerizing agents, stabilizers, antioxidants, light absorbing agents for protecting light- sensitive fills, preservatives and the like. Preferably, the unit dosage of the fat blend in the food supplements is from 1 mg to 1000 mg (more preferably from 100 mg to 750 mg). The amount of the fat blend that is used in a unit dosage form is preferably from 100 mg to 2000 mg, for example 250 mg to 1500 mg (e.g., 750 mg), for example for taking four times a day.
The compositions of the invention may contain other additives that are well known in the art of food and pharmaceutical products including, but not limited to, flavouring ingredients, colouring agents, sweeteners and emulsifiers.
According to the invention, certain fat blends are useful for increasing the levels of docosahexaenoic acid (DHA) in the blood of a subject by oral consumption. The fat blends comprise ALA, CLA and greater than 15 %, more preferably greater than 20 %, such as greater than 30% or greater than 40 %, by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend. Preferably, the ratio of ALA/CLA is from 0.3 to 0.6. Typically, the fat blends will be fat blends of the invention as defined above.
Thus, the invention provides a method for increasing the levels of DHA in the blood of a subject which comprises providing the subject with a fat blend of the invention for oral consumption. The fat blend is typically simply provided to the subject for oral consumption, either in the form of the fat blend itself, a food product or a nutritional supplement. Preferably, the subject is in need of increasing the level of DHA in the blood. The subject is preferably a mammal, most preferably a human.
The fat blends of the invention may be used to increase the level of DHA in vitro. This may have a number of benefits. For example, the fat blends may be useful in treating or preventing one or more conditions selected from neurodegenerative diseases, depression, Alzheimer's disease, obesity and cardiovascular disease. Alternatively or additionally, the fat blends may be useful for improving one or more of brain function, brain development, retinal function and retinal development.
The invention may involve the use of oleic acid to increase the effect of ALA and CLA in increasing the level of DHA in vitro, for example in fat blends according to the invention.
The following non-limiting examples illustrate the invention and do not limit its scope in any way. In the examples and throughout this specification, all percentages, parts and ratios are by weight unless indicated otherwise.
Examples
Example 1
Rats were fed different levels of ALA1 CLA and oleic acid. The dietary groups are presented in Table 1.
TABLE 1
% of olive oil, CLA and linseed oil (LO) in the dietary groups
Clarinol™ G80 is CLA in the form of a triglyceride available from Lipid Nutrition BV, Wormerveer, The Netherlands.
Plasma from the rats was analysed. The results are set out in Table 2.
Dietary Unseesd oil
Group OA ClA (LO) LO/CLA DHA ALA CLA mean SD mean SD mean SD
1 2 0,5 3,5 7,0 170,65 24,35 315,64 69,43 20,53 3,97
2 2 1,0 3,0 3,0 223,68 35,84 300,13 74,29 45,51 11,07
3 2 1,5 2,5 1,7 255,53 28,11 271,35 30,86 89,91 20,77
4 2 2,0 2,0 1,0 276,88 42,69 256,14 69,94 133,89 40,64
5 2 2,5 1,5 0,6 312,95 50,97 197,30 63,63 245,25 28,72
6 2 3,0 1,0 0,3 318,57 35,49 170,32 34,34 280,26 28,38
TABLE 2
Plasma levels (nmoles/ml of plasma) of DHA, ALA and CLA.
Figure 1 shows the linear regression of DHA plasma concentration in function to linseed oil (LO)/CLA ratio in the diet. Figure 2 shows the logarithmic regression of alpha linolenic acid (ALA) and CLA plasma concentrations in function to linseed oil/CLA ratio in the diet.
The data show that unexpectedly the highest yield in DHA was obtained with a ratio of ALA/CLA between 0.3-0.6 (see Table 2) and increased linearly in relation to ALA/CLA ratio (Figure 1). Plasma levels of ALA and CLA were proportional, even though not linearly, to the amount present in the diet (Figure 2).
Example 2
The following is an example of a yoghurt according to the invention.
Formulation (%):
Ingredient Dosage [%] Dosage white mass overall [%
Semi-skimmed milk 1.5% fat 90.920 72.736
Sugar 4.000 3.2
Skimmed milk powder 1.900 1.52
Fat blend 1.875 1.5
Whey protein powder (30% protein) 1.300 1.04
Direct starter culture 0.005 0.004
Sugar syrup 42% (w/w) aseptic 13.808
Strawberry puree °Brix aseptic 6.208
The fat blend contains 42 % Clarinol™ G80, 25 % linseed oil and 33 % olive oil and comprises:
(i) 33 % CLA; (ii) 13 % ALA; and (iii) 34 % oleic acid; the percentages being based on the total weight of C16 to C20 fatty acids in the blend.
A 10% pre-emulsion of the fat blend in milk is made by slowly mixing in the fat blend to milk of 60 0C under high-shear mixing. The mixture is homogenised dual-stage at 200/50 bar and the resulting emulsion is cooled to 4 0C. Dry blend sugar, milk powder and whey protein is mixed with the rest of the milk. Then the pre-emulsion is added. The milk is heated to 60 0C, homogenized dual-stage at 160/40 bar and heated 2 minutes at 95 0C. The milk is cooled to a fermentation temperature of 32 0C. Starter culture is added to the milk at 32 0C and milk is fermented till pH 4.3-4.5. The resulting yoghurt is cooled to about 20 "C1 stirred and sugar syrup and fruit are added to the yoghurt.
Example 3
Soft gel capsules are produced by rotary die processing. The material for the outside shell of the capsules, the gel, and the fill are formulated separately. Once the gel mass and the fill mass are ready, the gel is spread into thin film to form two gelatin ribbons which are then rolled over two separate dies which determine the size and the shape of the capsules. As the gelatin films adapt to the dies, a fat blend of the invention comprising alpha-linolenic acid, conjugated linoleic acid and oleic acid is carefully dosed to a level of 500mg, 750mg or "lOOOmg oil per capsule and injected between the two gelatin ribbons which are sealed immediately afterwards by applying heat and pressure. Capsules fall from the machine and are then dried under a stream of hot air.
Example 4
This example shows the effect of oleic acid on CLAJLO mixture in DHA formation. Total fat was balanced by adding coconut oil (CO) (diets 1 and 2) or increasing CLA and linseed oil (LO) keeping the same CLA/LO ratio.
Materials and Methods
Animals and diets
30 male Wistar rats (Harlan, Milan, Italy), with an average initial weight of 150- 170 g, were divided into 5 groups, and fed for 3 weeks 5 different diets. The diets were based on the AIN-93G formulation, with substitution of soybean oil with a blend of oils (olive oil, linseed oil, CLA and coconut oil, see Table 3 for ratios) which allowed the 5 diets to be equal for total fatty acids. All experiments were performed in accordance with the guidelines and protocols approved by the European Union (EU Council 86/609; D.L 27.01.1992, No. 116) and by the
Animal Research Ethics Committee of the University of Cagliari. Measurement of plasma fatty acid profile
Total lipids were extracted from plasma using the Folch method. Aliquots were mildly saponified in order to obtain free fatty acids for HPLC analysis. Separation of fatty acids was carried out with a Hewlett-Packard 1100 HPLC system (Hewlett-Packard, Palo Alto, California, USA) equipped with a diode array detector. A C-18 lnertsil 5 ODS-2 Chrompack column (Chrompack International BV, Middleburg, The Netherlands), 5 μm particle size, 15O x 4.6 mm, was used with a mobile phase of CH3CN/H2O/CH3COOH (70/30/0.12, v/v/v) at a flow rate of 1.5 ml/min. Unsaturated fatty acids were detected at 200 nm. Spectra (195-315 nm) of the eluate were obtained every 1.28 s and were electronically stored. These spectra were taken to confirm the identification of the HPLC peaks.
Results
The data show that the highest yield in DHA was obtained with 2% of olive oil (Table 4). Lower levels of plasma DHA were detected when either olive oil was replaced with coconut oil or higher levels of CLA and linseed oil (Figures 3 and 4).
Figure 3 shows linear regression of DHA plasma concentration in function to olive oil in the diet when olive oil was replaced with coconut oil.
Figure 4 shows linear regression of DHA plasma concentration in function to olive oil in the diet when olive oil was replaced by increasing CLA and linseed oil (LO) keeping the same CLA/LO ratio.
Tables and Figures
* comparative
TABLE 3. % of olive oil (OA), CLA, linseed oil (LO) and coconut oil (CO) in the dietary groups of Example 4
Dietary % of oils Plasma levels (nmoles/ml)
CO CLA LO OO DHA ALA CLA
229.12 193.97 285.44
2 2.5 1.5 0
58.52 44.00 65.63
268.30 181.37 265.79
1 2.5 1.5 1
61.04 42.91 41.94
356.85 164.20 246.83
0 2.5 1.5 2
51.62 32.07 30.48
282.55 176.33 311.49
0 3.2 1.9 1
38.71 26.39 13.74
257.28 207.22 349.58
0 3.8 2.3 0
20.21 41.33 56.10
TABLE 4. Plasma levels (nmoles/ml of plasma) of DHA, ALA and CLA in rats fed a mixture of olive oil (00), CLA, linseed oil (LO) and coconut oil (CO) for 3 weeks

Claims

Claims
1. A fat blend comprising alpha-linolenic acid, conjugated linoleic acid and oleic acid, wherein the fat blend comprises:
(i) greater than 3 % by weight alpha-linolenic acid;
(ii) greater than 12 % by weight conjugated linoleic acid; and
(iii) greater than 20 % by weight oleic acid,
the percentages being based on the total weight of C16 to C20 fatty acids in the blend.
2. Fat blend as claimed in Claimi , wherein the alpha-linolenic acid is present in an amount of greater than 5 % by weight based on the total weight of C16 to C20 fatty acids in the blend.
3. Fat blend as claimed in Claim 1 or Claim 2 comprising from 7 % to 65 % by weight alpha-linolenic acid, the percentage being based on the total weight of C16 to C20 fatty acids in the blend.
4. Fat blend as claimed in any one of the preceding claims comprising from 16 % to 77 % by weight conjugated linoleic acid, the percentage being based on the total weight of C16 to C20 fatty acids in the blend.
5. Fat blend as claimed in one of the preceding claims comprising from 25 % to 82 % by weight oleic acid, the percentage being based on the total weight of C16 to C20 fatty acids in the blend.
6. Fat blend as claimed in any one of the preceding claims, wherein at least a part of the alpha-linolenic acid in the blend is provided by the presence in the fat blend of linseed oil.
7. Fat blend as claimed in any one of the preceding claims, wherein at least a part of the oleic acid in the blend is provided by the presence in the fat blend of olive oil.
8. Fat blend as claimed in any one of the preceding claims, which comprises linseed oil, olive oil and a source of conjugated linoleic acid.
9. Fat blend as claimed in any one of the preceding claims, which is suitable for human consumption.
10. Use of a fat blend comprising alpha-linolenic acid, conjugated linoleic acid and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, for increasing the levels of docosahexaenoic acid in the blood of a subject by oral consumption.
11. Fat blend comprising alpha-linolenic acid, conjugated linoleic acid and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, for increasing the levels of docosahexaenoic acid in the blood of a subject by oral consumption.
12. Method for increasing the levels of docosahexaenoic acid in the blood of a subject which comprises providing the subject with a fat blend a fat blend comprising alpha-linolenic acid, conjugated linoleic acid and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, for oral consumption.
13. Use of a fat blend comprising alpha-linolenic acid, conjugated linoleic acid and greater than 15 % by weight oleic acid based on the total weight of C16 to C20 fatty acids in the blend, in the manufacture of a composition: for treating or preventing one or more conditions selected from neurodegenerative diseases, depression, Alzheimer's disease, obesity and cardiovascular disease; or for improving one or more of brain function, brain development, retinal function and retinal development.
14. Use of Claim 10, fat blend of Claim 11 , method of Claim 12 or use of Claim 13, wherein the fat blend is as defined in any one of Claims 1 to 9.
15. Foodstuff or nutritional supplement comprising a fat blend as claimed in any one of Claims 1 to 9.
EP10725974A 2009-05-22 2010-05-21 Fat blends and uses thereof Withdrawn EP2432328A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10725974A EP2432328A1 (en) 2009-05-22 2010-05-21 Fat blends and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09251383 2009-05-22
EP10725974A EP2432328A1 (en) 2009-05-22 2010-05-21 Fat blends and uses thereof
PCT/EP2010/003126 WO2010133377A1 (en) 2009-05-22 2010-05-21 Fat blends and uses thereof

Publications (1)

Publication Number Publication Date
EP2432328A1 true EP2432328A1 (en) 2012-03-28

Family

ID=41202607

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10725974A Withdrawn EP2432328A1 (en) 2009-05-22 2010-05-21 Fat blends and uses thereof

Country Status (2)

Country Link
EP (1) EP2432328A1 (en)
WO (1) WO2010133377A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140037813A1 (en) * 2012-08-02 2014-02-06 Mead Johnson Nutrition Company Nutritional creamer composition
CN103783160A (en) * 2014-02-21 2014-05-14 普洱联众生物资源开发有限公司 Functional yoghourt rich in unsaturated fattyacids
EP3111930B1 (en) * 2015-06-30 2018-04-18 Bierwirth, Rolf Composition for treating depression, bipolar disorders, recurrent medical depressive disorders and other long-term affective disorders
CN115245510A (en) * 2021-04-28 2022-10-28 扬州大学 Application of trans-10, cis-12 conjugated linoleic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2161969T3 (en) * 1995-11-14 2001-12-16 Unilever Nv EDIBLE FAT TO SPREAD.
JP4212590B2 (en) * 2003-04-25 2009-01-21 イルシンウェルズ コーポレーション リミティッド High purity diglyceride oil composition containing conjugated linoleic acid and method for producing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010133377A1 *

Also Published As

Publication number Publication date
WO2010133377A8 (en) 2012-01-05
WO2010133377A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
US11297873B2 (en) Ketogenic nutritional compositions
EP1685834B1 (en) Use of pinolenic acid for the treatment of obesity
US20240148690A1 (en) Compositions comprising urolithin compounds
ES2202454T3 (en) USE OF A BALANCING AGENT FOR OMEGA-3 AND OMEGA-6 Unsaturated FATTY ACIDS.
FR2955459A1 (en) OIL COMPOSITION RICH IN MONOGLYCERIDES OF DHA
US20090099261A1 (en) Omega-3 mixtures
US20130102673A1 (en) Method of treating an edible oil
JP3614859B2 (en) Nervonic acid composition
JPH03504868A (en) Structured lipids containing milk fat
WO2010133377A1 (en) Fat blends and uses thereof
KR100913689B1 (en) Aqueous nanoemulsion composition containing conjugated linoleic acid
AU728842B2 (en) Dairy products with enhanced CLA content
KR100684641B1 (en) Oil composition, food and health food containing the same
US9149050B2 (en) Use of conjugated linoleic acid
JP6824506B2 (en) Lipid composition
JP5479696B2 (en) In vivo plasmalogen increasing agent
CN106232113B (en) Absorption enhancer for unsaturated fatty acid
US20220409640A1 (en) Methods using phosphatidylserine powder
EP2002729A1 (en) Use of pinolenic acid for lowering cholesterol
Hayam et al. Health promoting effect of polyunsaturated fatty acids (omega-3 and omega-6) in milk and milk products (Short Review)
EP2002731A1 (en) Use of pinolenic acid for increasing lean body mass
EP2002730A1 (en) Pinolenic acid compositions for treating fatty liver

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130319